Publications by authors named "Lisena Cala"
Article Synopsis
- Metastasis-directed therapy has potential benefits for patients with oligometastatic disease (OMD), but breast cancer studies have not yet confirmed these benefits through randomized trials.
- A study at the Technical University of Munich analyzed 80 patients using F-FDG PET/CT images to better define OMD, revealing that nearly half the time, this imaging method significantly changed the assessment of metastatic disease compared to conventional CT.
- F-FDG PET/CT discovered additional metastases in a third of cases, highlighting the need for clearer standards in imaging definitions for future research and clinical practices in breast cancer treatment.
β-emitting Lu targeting prostate-specific membrane antigen (PSMA) is an approved treatment option for metastatic castration-resistant prostate cancer. Data on its long-term nephrotoxicity are sparse. This study aimed to retrospectively evaluate post-Lu-PSMA estimated glomerular filtration rate (eGFR) dynamics for at least 12 mo in a cohort of metastatic castration-resistant prostate cancer patients.
View Article and Find Full Text PDFProstate-specific antigen (PSA) is widely used to monitor treatment response in patients with metastatic castration-resistant prostate cancer. However, PSA measurements are considered only after 12 wk of treatment. We aimed to evaluate the prognostic value of early PSA changes after Lu-labeled prostate-specific membrane antigen (Lu-PSMA) radionuclide treatment in metastatic castration-resistant prostate cancer patients.
View Article and Find Full Text PDFBackground: Aspirin administration, as part of a dual antiplatelet treatment regimen, is essential for patients undergoing percutaneous coronary intervention (PCI). Although the correlation between high on-clopidogrel treatment platelet reactivity (HCPR) and clinical outcome is well established, data for high on-aspirin treatment platelet reactivity (HAPR) are conflicting.
Objectives: The aim of the ISAR-ASPI (Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition) registry was to assess the value of HAPR as a possible prognostic biomarker in PCI-treated patients with regard to clinical outcome.